Page last updated: 2024-11-06

pemirolast

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pemirolast is a non-sedating antihistamine that is used to treat allergic rhinitis, also known as hay fever. It is a selective antagonist of histamine H1 receptors. Pemirolast is available as an oral tablet and as a nasal spray. The compound is a white to off-white crystalline powder. It is freely soluble in methanol, ethanol, and acetone, but it is practically insoluble in water. Pemirolast was initially developed by Otsuka Pharmaceutical Co., Ltd. It is now marketed by various pharmaceutical companies worldwide. Pemirolast is thought to work by blocking the effects of histamine, a chemical that is released by the body during an allergic reaction. When histamine is released, it binds to H1 receptors on cells, causing symptoms such as sneezing, runny nose, and itchy eyes. By blocking histamine from binding to these receptors, pemirolast helps to relieve these symptoms. Pemirolast is generally well tolerated. The most common side effects are headache, drowsiness, and dry mouth. Pemirolast is a relatively new drug, and its long-term effects are not yet fully known. However, it is believed to be safe and effective for the treatment of allergic rhinitis.'

pemirolast: RN from Toxlit; structure given in first source; antiallergic drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID57697
CHEMBL ID1201198
CHEBI ID134936
SCHEMBL ID29036
MeSH IDM0155363

Synonyms (47)

Synonym
BIDD:GT0717
pemirolastum
unii-2c09nv773m
2c09nv773m ,
DB00885
pemirolast
pemirolastum [inn-latin]
9-methyl-3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidin-4-one
4h-pyrido(1,2-a)pyrimidin-4-one, 9-methyl-3-(1h-tetrazol-5-yl)-
hsdb 7291
pemirolast [inn]
CHEBI:134936
9-methyl-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one
L000978
69372-19-6
D07476
pemirox (tn)
pemirolast (inn)
CHEMBL1201198
pemirox
permirolast
bdbm50323686
pemiroplast potassium
FT-0630784
9-methyl-3-(2h-1,2,3,4-tetrazol-5-yl)-4h-pyrido[1,2-a]pyrimidin-4-one
gtpl7329
pemirolast [who-dd]
pemirolast [vandf]
pemirolast [hsdb]
pemirolast [mi]
permirolast [vandf]
HIANJWSAHKJQTH-UHFFFAOYSA-N
9-methyl-3-(1h-tetrazol-5-yl)-4h-pyrido[1,2-a]pyrimidin-4-one
9-methyl-3-(1h-tetrazol-5-yl)-4h-pyrido-[1,2-a]-pyrimidin-4-one
9-methyl-3-(1 h-tetrazol-5-yl)-4h-pyrido-[1,2-a]-pyrimidin-4-one
SCHEMBL29036
DTXSID1048338
HY-137863
4h-pyrido[1,2-a]pyrimidin-4-one,9-methyl-3-(2h-tetrazol-5-yl)-
bmy 26517; bmy 26517; bmy 26517
BCP21140
Q7162004
SB18791
A866853
9-methyl-3-(2h-tetrazol-5-yl)-4h-pyrido[1,2-a]pyrimidin-4-one
CS-0142437
EN300-37158601

Research Excerpts

Overview

Pemirolast is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma. PemirolAST is a potent, long-acting, orally effective antiallergic agent.

ExcerptReferenceRelevance
"Pemirolast is a new oral, nonbronchodilator antiallergy medication that is being evaluated for the therapy of asthma. "( Pemirolast, a new oral nonbronchodilator drug for chronic asthma.
Bernstein, IL; Bierman, CW; Kemp, JP; Li, JT; Siegel, SC; Spangenberg, RD; Tinkelman, DG, 1992
)
3.17
"Pemirolast is a potent, long-acting, orally effective antiallergic agent evaluated for clinical activity in prevention of symptoms of seasonal allergic rhinitis. "( A pilot study of pemirolast in patients with seasonal allergic rhinitis.
Berkowitz, RB; Tinkelman, DG, 1991
)
2.06

Effects

ExcerptReferenceRelevance
"Pemirolast has a preventive effect against restenosis after stent placement, possibly by inhibiting neointimal hyperplasia."( Preventive effect of an antiallergic drug, pemirolast potassium, on restenosis after stent placement: quantitative coronary angiography and intravascular ultrasound studies.
Aoyagi, K; Hitsumoto, T; Iizuka, T; Kaku, M; Kanai, M; Matsumoto, J; Noike, H; Ohsawa, H; Sakuragawa, H; Sakurai, T; Shimizu, K; Sugiyama, Y; Takahashi, M; Tokuhiro, K; Tomaru, T; Yoshinaga, K, 2003
)
2.02
"Pemirolast has a preventive effect against restenosis after stent placement, possibly by inhibiting neointimal hyperplasia."( Preventive effect of an antiallergic drug, pemirolast potassium, on restenosis after stent placement: quantitative coronary angiography and intravascular ultrasound studies.
Aoyagi, K; Hitsumoto, T; Iizuka, T; Kaku, M; Kanai, M; Matsumoto, J; Noike, H; Ohsawa, H; Sakuragawa, H; Sakurai, T; Shimizu, K; Sugiyama, Y; Takahashi, M; Tokuhiro, K; Tomaru, T; Yoshinaga, K, 2003
)
2.02

Treatment

ExcerptReferenceRelevance
"Treatment with pemirolast did not retard the growth of medium-sized AAAs."( Randomized clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm.
Bredahl, K; Eldrup, N; Hultgren, R; Lindeman, J; Sillesen, H; Swedenborg, J; Thompson, M; Wanhainen, A; Wingren, U, 2015
)
0.77

Toxicity

ExcerptReferenceRelevance
" Both regimens were well tolerated with no differences in adverse events were observed."( A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis.
Gous, P; Ropo, A, 2004
)
0.56

Dosage Studied

ExcerptRelevanceReference
" In this single-center, 7-day, prospective, double-blind, single-dose, crossover, parallel-group study, subjects were randomized to be bilaterally dosed with pemirolast, cromolyn, or ketorolac at each of 3 visits."( A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents.
Amdahl, L; Graves, A; Shulman, DG; Washington, C, 2003
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridopyrimidineAny organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G protein-coupled receptor GPR35Rattus norvegicus (Norway rat)EC50 (µMol)0.09500.06110.38070.9860AID1354836
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1354836Agonist activity at recombinant rat N-terminal FLAG/eYFP-fused GPR35 expressed in HEK293 cells assessed as induction of beta-arrestin recruitment by BRET assay2018ACS medicinal chemistry letters, May-10, Volume: 9, Issue:5
SAR Studies of
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (13.33)18.7374
1990's18 (40.00)18.2507
2000's14 (31.11)29.6817
2010's6 (13.33)24.3611
2020's1 (2.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.29 (24.57)
Research Supply Index4.11 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index63.56 (26.88)
Search Engine Supply Index2.25 (0.95)

This Compound (40.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (27.66%)5.53%
Reviews1 (2.13%)6.00%
Case Studies2 (4.26%)4.05%
Observational0 (0.00%)0.25%
Other31 (65.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Placebo-controlled, Cross-over, Study to Assess the Efficacy of the Oral Mast Cell Inhibitor Pemirolast in Allergen-induced Airway Obstruction and Inflammation in Subjects With Allergic Asthma [NCT03119714]Phase 21 participants (Actual)Interventional2016-11-30Terminated(stopped due to Due to results from other studies regarding efficacy of pemirolast)
A Double-Blind, Randomised, Placebo-controlled, Cross-over, Phase 2 Mannitol Challenge Trial, Investigating the Efficacy of CRD007 in Adult Subjects With Asthma [NCT02609334]Phase 224 participants (Actual)Interventional2015-03-31Completed
A Double-Blind, Randomised, Placebo-controlled, Parallel Group, International, Multi-centre Phase 2 Trial Investigating the Safety and Efficacy of CRD007 in Adult Subjects With Asthma [NCT02615080]Phase 2168 participants (Actual)Interventional2015-11-30Completed
An Open-label, Single Center, Phase I, Dose Escalation Study Investigating the Safety, Tolerability and Pharmacokinetics of Pemirolast in Healthy Subjects [NCT02517372]Phase 124 participants (Actual)Interventional2014-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]